Navigation Links
European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder
Date:6/26/2008

sustained period of at least six months.(12)

"If left untreated, symptoms of Generalised Anxiety Disorder may progress to prevent patients from working and operating in daily social situations," said Dr. Christer Allgulander of the Department of Clinical Neuroscience, Karolinska Institutet in Stockholm. "According to population and primary care surveys the majority of people suffering from anxiety, and their physicians, still have unmet needs. This positive opinion on duloxetine creates another effective pharmacotherapy option that will help patients feel better, and help physicians in their aim to improve functioning for those suffering from this debilitating condition."

Duloxetine, a member of a class of drugs commonly referred to as serotonin and noradrenaline reuptake inhibitors,(13) is already approved to treat major depressive disorder and diabetic peripheral neuropathic pain. Duloxetine gained marketing authorisation for the treatment of GAD in Mexico in 2006 and in the United States in 2007.

Notes to Editors:

About Generalised Anxiety Disorder

Approximately nine million Europeans (8,9) and six million people in Central and South America are estimated to suffer from GAD.(10) Quality of life is affected as symptoms of GAD can include exaggerated worry or chronic anxiety, irritability and poor concentration. Ability to work is often compromised with the manifestation of physical symptoms such as muscle tension, fatigue, sleep disturbance and nausea.(12) The illness tends to be chronic with periods of exacerbation and remission. Patients report that episodes of generalized anxiety disorder are often brought on, or worsened, by stressful life events.(14)

About Duloxetine

While duloxetine's mechanism of action in humans is not fully known, it is believed to affect both serotonin and norepinephrine/noradrenaline mediated nerve signalling in the brain and the spinal cord. Based on pre-clinical studies, duloxeti
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
2. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
3. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
4. XTENT Announces European Regulatory Update
5. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
6. Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
7. European Unions CHMP Issues Positive Opinion on Sugammadex
8. PLC Systems Announces Approval of First European Study to Evaluate RenalGuard(TM)
9. PRoFESS(R) Results Announced at XVII European Stroke Conference
10. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
11. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
(Date:1/15/2014)... 2014  Novation, the leading health care supply chain expertise, ... reseller (VAR) national contracts that expand its portfolio to ... lower costs. These include manufacturer product and service agreements, ... and ongoing IT consulting support. New ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... , FRIMLEY, England, December 8 , ... Treatment Effectiveness,in the Trial, in Patients With Newly-Diagnosed Disease(1) , ... the Disease on nilotinib (300mg Twice-Daily and 400mg Twice-Daily) Than on,imatinib 400mg ... Only a Small Number of Patients,Discontinued Due to Adverse Events(1) , ...
... ... , ... - Will Use BrainTrack,s College Campus Data to Enhance Elsevier Evolve,Website Registrations ... technical and,medical information products and services, and BrainTrack,( http://www.braintrack.com ), the widely referenced ...
Cached Medicine Technology:Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Elsevier Selects BrainTrack Directory as Supplier of College Data 2Elsevier Selects BrainTrack Directory as Supplier of College Data 3Elsevier Selects BrainTrack Directory as Supplier of College Data 4
(Date:4/18/2014)... San Diego, Calif. (April 18, 2014) ― A new ... analyzing weekly patterns in health-related Google searches reveals ... public health strategies. , Investigators from San ... University, and the Monday Campaigns, analyzed "healthy" Google searches ... health-related, e.g., "healthy diet") originating in the U.S. from ...
(Date:4/17/2014)... The presence of chronic inflammation in benign ... prostate cancer, and this association was found even ... according to a study published in Cancer ... the American Association for Cancer Research. , An ... participants of the placebo arm of the Prostate ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... issue of Experimental Biology and Medicine ... Gaskins and Paul Kenis in the Institute of ... University of Illinois Urbana-Champaign describe their recent work ... a variety of cell functions including energy metabolism, ... roles in regulating normal cellular behavior, redox status ...
(Date:4/17/2014)... in the April issue of Immunity , Kevin ... Medical Research, says it,s time to take a fresh ... sepsis, which kills millions worldwide every year, including ... released into the bloodstream to fight an injury or ... for maintaining good health without inflammation, wounds and ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:New pain relief targets discovered 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2
... IDXX ), announced today that its Board of ... additional four million,shares of its common stock under its ... open market or in negotiated transactions.,These shares are in ... 2007, under a previous Board authorization. The timing and,amount ...
... Consumer,Healthcare, a division of Wyeth (NYSE: WYE ... named Executive Vice President, Global Research and,Development (R&D), ... the consumer division,s global R&D organization. In her ... R&D efforts to,effectively bring new products to market ...
... Researchers find chronic worry impairs immune response to cancer-causing ... levels of daily stress could explain why some women ... cervical cancer, a new study suggests. , Scientists ... women, all diagnosed with cervical dysplasia (precancerous cervical lesions), ...
... Precious Medicare Dollars on Trial Lawyers and,Focus on Needy ... Blunt (Mo.) today praised President Bush,s proposal that would ... is clear that without substantial reforms, Medicare will not ... The legislation put,forth by the president is the needed ...
... million in bonuses and incentives, ADA, Mich., Feb. ... $1.072 billion, the fifth consecutive year in which the,company ... from the previous year,s sales of $1.12 billion, which ... affected minimally by actions the company took to,terminate the ...
... media outreach for TRIA, the first hair removal ... to enter U.S. home-based beauty device market, NEW ... Rpr Marketing Communications as its U.S. agency of record ... U.S. home-based beauty,device market., SpectraGenics, Inc. is a ...
Cached Medicine News:Health News:Wyeth Consumer Healthcare Names New Head of Global R&D 2Health News:Daily Stress May Raise Women's Risk of Cervical Cancer 2Health News:Daily Stress May Raise Women's Risk of Cervical Cancer 3Health News:Blunt Praises President's Plan to Save Medicare 2Health News:Quixtar Announces Fifth Consecutive Year of Billion-Dollar Sales 2Health News:Spectragenics Names Rpr Marketing Communications Agency of Record 2
Microforceps : Eckardt End & Side Gripping Forceps...
Blunt tipped forceps wlth a small grasping platform on each tip. For grasping fine membranes or grasping membranes adherent to the retinal surface....
Microforceps: Spaid Pic Forceps...
Blunt tipped forceps with small, slightly pointed grasping platforms on each tip. For general purpose (fine) membrane grasping and grasping membranes adherent to the retlnal surface....
Medicine Products: